NanoViricides Inc. (NNVC)
| Bid | 1.18 |
| Market Cap | 18.61M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -10.05M |
| EPS (ttm) | -0.71 |
| PE Ratio (ttm) | -1.68 |
| Forward PE | -1.93 |
| Analyst | Buy |
| Ask | 1.25 |
| Volume | 153,509 |
| Avg. Volume (20D) | 380,820 |
| Open | 1.28 |
| Previous Close | 1.32 |
| Day's Range | 1.18 - 1.30 |
| 52-Week Range | 1.03 - 3.59 |
| Beta | 1.35 |
About NNVC
NanoViricides, Inc., a nano-biopharmaceutical research and development company, discovers, develops, and commercializes drugs for the treatment of viral infections. The company develops Human Coronavirus Program for COVID-19 seasonal coronavirus affliction; HerpeCide Dermal Topical and Eye Drops for the treatment of shingles, PHN, chickenpox, herpes, recurrent herpes labialis, genital herpes, and ocular herpes keratitis; and HerpeCide IntraOcular...
Analyst Forecast
According to 1 analyst ratings, the average rating for NNVC stock is "Buy." The 12-month stock price forecast is $6.5, which is an increase of 446.22% from the latest price.
1 week ago · proactiveinvestors.com
NanoViricides targets key milestones in 2025 with NV-387 advancing to Phase II trialsNanoViricides (NYSE-A:NNVC) is positioning itself for a pivotal year in 2025, with plans to advance its lead antiviral candidate, NV-387, into multiple Phase II clinical trials. The company is plannin...
2 weeks ago · proactiveinvestors.com
NanoViricides announces readiness to combat bird flu with antiviral drug NV-387NanoViricides (NYSE-A:NNVC) stated today that it is prepared to address the escalating threat of bird flu with its broad-spectrum antiviral drug, NV-387. The company asserts that NV-387 is designed to...
2 weeks ago · accessnewswire.com
NanoViricides Drug Can Fight Bird Flu Pandemic; H5N1 Virus Cannot EscapeSHELTON, CT / ACCESS Newswire / February 11, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company") declared today that it is ready to fight the bird flu with its revolutionary broad-spectrum...
4 weeks ago · proactiveinvestors.com
NanoViricides seeks to eliminate treatment delays with its broad spectrum antiviral NV-387With its broad-spectrum antiviral drug NV-387, NanoViricides (NYSE-A:NNVC) sees a future where patients with a range of viral diseases can access treatment as quickly as they can secure antibiotics fo...
1 month ago · proactiveinvestors.com
NanoViricides warns of bird flu pandemic as outbreak spreads in MassachusettsBird flu is likely widespread among birds in Massachusetts, State health and environmental officials said this week on Wednesday, as new cases are reported in both wild and domestic birds across multi...
1 month ago · accessnewswire.com
NanoViricides to Present at the MicroCap Conference on Wednesday, January 29, 2025SHELTON, CT / ACCESS Newswire / January 29, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing revolutionary broad-spectrum antiviral drugs that the vi...
1 month ago · proactiveinvestors.com
NanoViricides taps clinical research organization for Phase II trial of NV-387NanoViricides (NYSE-A:NNVC) said on Monday it had engaged a clinical research organization to conduct a Phase II trial for its broad-spectrum antiviral drug NV-387. The Connecticut-based company is ta...
1 month ago · proactiveinvestors.com
NanoViricides CEO discusses NV-387's broad spectrum promise - ICYMINanoViricides (NYSE-A:NNVC) CEO Dr Anil Diwan joined Proactive to highlight the company's lead drug candidate NV-387, which is targeting multiple viral families by mimicking receptors essential for vi...